MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Evolus Deferred Revenue 2011-2025 | EOLS
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Evolus
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.5 M | 11 M | 9.01 M | 7.93 M | 3.08 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.5 M | 3.08 M | 9.1 M |
Quarterly Deferred Revenue Evolus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.58 M | 8.73 M | 7.57 M | 14.5 M | 13.2 M | 11.8 M | 8.71 M | 11 M | 8.78 M | 8.94 M | 6.98 M | 9.01 M | 10.2 M | - | 4.99 M | 7.93 M | 5.75 M | 4.53 M | 3.11 M | 3.08 M | 3.08 M | 3.08 M | 3.08 M | 1.71 M | 1.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.5 M | 1.71 M | 7.09 M |
Deferred Revenue of other stocks in the Drug manufacturers industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assertio Holdings
ASRT
|
200 K | $ 0.73 | -3.54 % | $ 51.9 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
85.4 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
49 K | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
27.8 K | - | 0.86 % | $ 117 M | USA |
 |
Aurora Cannabis
ACB
|
27 M | $ 5.17 | -4.22 % | $ 86.3 M |  Canada |
 |
Catalent
CTLT
|
250 M | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
8.21 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
545 K | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
600 K | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
27.2 M | $ 12.03 | 5.34 % | $ 616 M | USA |
 |
Pacira BioSciences
PCRX
|
102 K | $ 26.7 | 1.56 % | $ 1.23 B | USA |
 |
Athenex
ATNX
|
2.82 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
114 K | $ 21.39 | 0.14 % | $ 2.04 B |  France |
 |
Rockwell Medical
RMTI
|
46 K | $ 0.87 | -5.71 % | $ 20.3 M | USA |
 |
Harrow Health
HROW
|
75 K | $ 45.82 | -2.64 % | $ 1.49 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
641 K | $ 3.51 | -2.11 % | $ 4.36 M | USA |
 |
China Pharma Holdings
CPHI
|
162 K | $ 1.55 | -0.26 % | $ 27.1 M |  China |
 |
Bausch Health Companies
BHC
|
26 M | $ 6.88 | -0.65 % | $ 2.51 B | Canada |
 |
Veru
VERU
|
400 K | $ 2.44 | 0.83 % | $ 329 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
207 K | $ 3.05 | 20.47 % | $ 42.9 M | USA |
 |
cbdMD
YCBD
|
503 K | $ 1.39 | 13.52 % | $ 5.99 M | USA |
 |
Solid Biosciences
SLDB
|
10.4 M | $ 5.81 | -1.11 % | $ 237 M | USA |
 |
Perrigo Company plc
PRGO
|
122 M | $ 12.86 | -2.17 % | $ 1.77 B | USA |
 |
ProPhase Labs
PRPH
|
2.5 M | $ 0.12 | 0.17 % | $ 1.9 M | USA |
 |
Radius Health
RDUS
|
1 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
543 K | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
160 K | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
1.19 M | $ 0.64 | -1.25 % | $ 30.6 M | USA |
 |
Tilray
TLRY
|
23.7 M | $ 11.6 | -4.56 % | $ 7.17 B | Canada |
 |
TherapeuticsMD
TXMD
|
523 K | $ 1.69 | -3.43 % | $ 17.6 M | USA |
 |
Zomedica Corp.
ZOM
|
276 K | - | -0.21 % | $ 98 M | USA |